Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 22, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Levothyroxine Sodium Tablets USP".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 22, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Levothyroxine Sodium Tablets USP".